These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21207222)

  • 1. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy.
    Sharili AS; Allen S; Smith K; Hargreaves J; Price J; McGonnell I
    Tumour Biol; 2011 Jun; 32(3):515-26. PubMed ID: 21207222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological relevance of tumour grading in canine osteosarcoma.
    Loukopoulos P; Robinson WF
    J Comp Pathol; 2007 Jan; 136(1):65-73. PubMed ID: 17270206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma.
    Yu L; Guo WC; Zhao SH; Tang J; Chen JL
    APMIS; 2010 Mar; 118(3):222-9. PubMed ID: 20132188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some prognostic and epidemiologic factors in canine osteosarcoma.
    Misdorp W; Hart AA
    J Natl Cancer Inst; 1979 Mar; 62(3):537-45. PubMed ID: 283283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
    Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
    Machado I; Navarro S; Picci P; Llombart-Bosch A
    Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and its clinical significance of heat shock protein gp96 in human osteosarcoma.
    Guo WC; Zhao SH; Yu L; Tang J; Wu GX; Chen JL
    Neoplasma; 2010; 57(1):62-7. PubMed ID: 19895174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma.
    Won KY; Park HR; Park YK
    Tumori; 2009; 95(3):311-6. PubMed ID: 19688969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various types of osteosarcomas.
    Chano T; Matsumoto K; Ishizawa M; Morimoto S; Hukuda S; Okabe H; Kato H; Fujino S
    Eur J Histochem; 1996; 40(3):189-98. PubMed ID: 8922947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor development.
    Sharili AS; Allen S; Smith K; Price J; McGonnell IM
    Cancer Lett; 2013 Jun; 333(2):170-9. PubMed ID: 23352643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer.
    Okada K; Hasegawa T; Yokoyama R; Beppu Y; Itoi E
    J Clin Pathol; 2003 Oct; 56(10):742-6. PubMed ID: 14514776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
    Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
    J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
    Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
    Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma.
    Yuan D; Liu B; Liu K; Zhu G; Dai Z; Xie Y
    J Surg Oncol; 2013 Sep; 108(3):157-62. PubMed ID: 23813624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study.
    Oda Y; Naka T; Takeshita M; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2000 Jun; 31(6):709-16. PubMed ID: 10872665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of multidrug resistance-associated protein 1 in osteosarcoma and its relationship with clinicopathologic characteristics].
    Tu C; Tian Y; Pei F
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):684-7. PubMed ID: 14619581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
    Jiang L; Liu J; Wei Q; Wang Y
    Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic heterogeneity in osteosarcomas.
    Hasegawa T; Hirose T; Kudo E; Hizawa K; Usui M; Ishii S
    Hum Pathol; 1991 Jun; 22(6):583-90. PubMed ID: 1864588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody.
    Yoshikawa H; Rettig WJ; Takaoka K; Alderman E; Rup B; Rosen V; Wozney JM; Lane JM; Huvos AG; Garin-Chesa P
    Cancer; 1994 Jan; 73(1):85-91. PubMed ID: 7506120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.